menu search

ATAI / Why Shares of Atai Life Sciences Rose Friday

Why Shares of Atai Life Sciences Rose Friday
Atai focuses on psychedelics to treat mental illnesses. The clinical-stage biopharmaceutical company said it has enough cash to last into 2026. Read More
Posted: Mar 31 2023, 14:49
Author Name: The Motley Fool
Views: 111663

ATAI News  

Psychedelics CEOs heartened by MDMA for PTSD study results as stocks maintain momentum

By Proactive Investors
September 15, 2023

Psychedelics CEOs heartened by MDMA for PTSD study results as stocks maintain momentum

The success of a Phase 3 trial of MDMA for post-traumatic stress disorder (PTSD) which has put the therapy on track for U.S. Food and Drug Administrat more_horizontal

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

By GlobeNewsWire
September 14, 2023

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company ai more_horizontal

atai Life Sciences to Participate in Upcoming September Investor Conferences

By GlobeNewsWire
September 6, 2023

atai Life Sciences to Participate in Upcoming September Investor Conferences

NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company ai more_horizontal

atai Life Sciences N.V. (ATAI) Loses -15.43% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

By Zacks Investment Research
September 6, 2023

atai Life Sciences N.V. (ATAI) Loses -15.43% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. more_horizontal

Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies

By Seeking Alpha
September 1, 2023

Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies

Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated with schizophrenia, with top-line results expected in the more_horizontal

Down -24.4% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)

By Zacks Investment Research
August 21, 2023

Down -24.4% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)

atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. more_horizontal

COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down

By Seeking Alpha
July 14, 2023

COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down

COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down more_horizontal

FDA issues guidance on psychedelic drug clinical trials

By Market Watch
June 23, 2023

FDA issues guidance on psychedelic drug clinical trials

The U.S. Food and Drug Administration on Friday issued its first draft guidance on psychedelic drug clinical trials, outlining considerations for comp more_horizontal


Search within

Pages Search Results: